Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Freenome Q3 2026 Results: Turns Profitable, Net Income $60.1M

Freenome, Inc. completed a business combination with Perceptive Capital Solutions Corp. on July 20, 2026, and is currently focused on developing blood-based screening tests like SimpleScreen CRC and SimpleScreen Lung. The company reports significant ongoing net losses and anticipates the need for additional capital to fund operations and commercialization efforts.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue183.51.0
Net income60.1-64.5
EPS (diluted, $ a share)$0.58$-0.95

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+17628.4%
Operating margin38.1%
Source

10-Q filed with the SEC, NASDAQ: FRNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Freenome, Inc.: key numbers

Share price
$10.09Close, Nov 16
Market cap
$1.13B
Shares outstanding
111.5MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Freenome, Inc.

All →
4:07 PM ET 8-K
Financial Results

Freenome Financial Results

Freenome reported its first quarterly results as a public company, highlighted by $183.5 million in revenue following the FDA approval of its SimpleScreen CRC blood test. The company achieved GAAP net income of $60.1 million, a significant turnaround from a net loss in the prior year, and ended the quarter with $430 million in cash and marketable securities.

Term
Q3 2026

“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”

Aaron Elliott, Ph.D., CEO of Freenome
8:53 AM ET 8-K
Product Launch

Freenome Product Launch

Freenome launched its SimpleScreen Lung test, a blood-based screening tool for adults aged 50-80 with a significant smoking history. The company also introduced a first-of-its-kind offering that allows eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw using two independently validated tests.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.